Baldwin Brothers LLC Crispr Therapeutics Ag Transaction History

Baldwin Brothers LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 12, 2024	BUY	$51.17 - $68.18 $204 - $272	4 New	4 $0
Q2 2022 Jul 18, 2022	SELL	$43.23 - $73.83 $1,729 - $2,953	-40 Reduced 20.73%	153 $9,000
Q1 2022 Apr 13, 2022	BUY	$53.19 - $79.24 $2,446 - $3,645	46 Added 31.29%	193 $12,000
Q4 2021 Jan 14, 2022	SELL	$70.09 - $111.29 $17,522 - $27,822	-250 Reduced 62.97%	147 $11,000
Q3 2021 Oct 27, 2021	BUY	$110.2 - $156.64 $4,297 - $6,108	39 Added 10.89%	397 $44,000
Q2 2021 Jul 30, 2021	BUY	$100.84 - $161.89 $4,033 - $6,475	40 Added 12.58%	358 $57,000
Q1 2021 Apr 08, 2021	BUY	$110.72 - $210.04 $27,680 - $52,510	250 Added 367.65%	318 $38,000
Q4 2019 Jan 29, 2020	BUY	$36.68 - $73.13 $2,494 - $4,972	68 New	68 $4,000

503

57.1M

1.74M

1.83M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.05B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Baldwin Brothers LLC, based on Form 13F filings with the SEC.

Stay updated on Baldwin Brothers LLC with notifications on news.